Eli Lilly Raises 2026 Guidance as GLP-1 Drug Demand Surges in Q1
Eli Lilly reported strong Q1 2026 financial results driven by massive growth in Mounjaro and Zepbound sales, leading the company to raise its full-year guidance amid surging demand for GLP-1 medications.
·1 source
